Hepatitis B e Antigen Seroconversion: A Critical Event in Chronic Hepatitis B Virus Infection
- First Online:
- 460 Downloads
Replication of hepatitis B virus (HBV) is the primary driver of disease progression and clinical outcomes in patients with chronic hepatitis B (CHB), but other factors, such as hepatitis B e antigen (HBeAg) status, also influence disease course. The importance of HBeAg seroconversion is underscored by current CHB treatment guidelines that recommend limiting the duration of antiviral therapy in HBeAg-positive patients who achieve seroconversion.
A 2-day meeting of leading hepatologists with extensive experience managing patients with CHB in the Asia–Pacific region was held with the overall goals of reviewing and evaluating (1) available data on the relationship between HBeAg seroconversion and clinical outcomes for patients with HBeAg-positive CHB, and (2) the ways in which seroconversion should influence patient management.
It was agreed that HBeAg seroconversion is an important serologic end point for patients with CHB and that achieving this goal should be an important consideration in treatment selection. Patients with HBeAg-positive CHB should consider pegylated interferon if they are aged <40 years (especially women), have lower HBV DNA levels, can afford this treatment, and have a lifestyle that would support adherence to injection therapy. Alternatively, nucleos(t)ide analogs are recommended in patients with alanine aminotransferase levels ≥2 × the upper limit of normal, HBV DNA levels <9 log10 IU/ml, and compensated CHB. Entecavir, telbivudine, and tenofovir may be used as first-line therapy; they can be administered as a finite therapeutic course in HBeAg-positive patients who seroconvert. Telbivudine and tenofovir should be considered in women of child-bearing potential.
KeywordsHepatitis B Hepatitis B e antigen seroconversion Oral nucleos(t)ide therapy Pegylated interferon
- 34.Chu CM, Liaw YF. Genotype C hepatitis B virus infection is associated with a higher risk of reactivation of hepatitis B and progression to cirrhosis than genotype B: a longitudinal study of hepatitis B e antigen-positive patients with normal aminotransferase levels at baseline. J Hepatol. 2005;43:411–417.CrossRefPubMedGoogle Scholar
- 40.Chu CM, Liaw YF. Hepatitis B surface antigen seroclearance during chronic HBV infection. Antivir Ther. 2010. doi:10.3851/IMP1497.
- 52.Heathcote JE, Gane E, deMan R. Two-year tenofovir disoproxil fumarate (TDF) treatment and adefovir dipivoxil (ADV) switch data in HBeAg-positive patients with chronic hepatitis B (study 103) (abstract no. 158). Hepatology. 2008;48(suppl 1):376A.Google Scholar
- 53.Heathcote EJ, Gane E, De Man RA, et al. Three years of tenofovir disoproxil fumarate (TDF) treatment in HBeAg-positive patients (HBeAg +) with chronic hepatitis B (Study 103). Hepatology. 2009;50:533A–534A.Google Scholar
- 58.Jia J, Hou J, Yin Y, et al. Prolonged efficacy and safety of 3 years of continuous telbivudine treatment in Chinese chronic hepatitis B (abstract no. FP034). Hepatol Int. 2009;2(suppl 1):43–44.Google Scholar
- 61.Wu Z, Yan W, Guo W, et al. Telbivudine preserves Th1 cytokine and inhibits Th2 cytokine production in MHV-3 induced viral hepatitis model. J Viral Hepat. 2010;17(suppl 1):1–10.Google Scholar